New pill for chronic hives enters first human tests

NCT ID NCT07686484

Not yet recruiting Disease control Sponsor: Atridia Pty Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This early-stage trial tests a single oral dose of HRS-3095, a new drug for chronic spontaneous urticaria (chronic hives), in 36 healthy adults. The main goal is to check safety and how the drug moves through the body. Results will guide future studies in patients with hives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-3095
What this could lead to: If successful, this could lead to a new oral treatment for chronic spontaneous urticaria (chronic hives).
What could go wrong: This is a very early, small study in healthy people, not patients. The drug may prove unsafe or ineffective in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Veritus Research

Bayswater, Victoria, 3153, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.